CSF3 and breast cancer: Among IR + 1 patients who did not receive G-CSF prophylaxis in cycle 1 (n = 352/409; 86.1%), incidence of FN was 4.8% (range: 0% [breast cancer] to 11.1% [NHL]) during cycle 1 and 15.9% (range: 10.3% [breast cancer] to 18.2% [lung cancer]) during the course.